Transcode Therapeutics, Inc. Logo

Transcode Therapeutics, Inc.

Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.

RNAZ | US

Overview

Corporate Details

ISIN(s):
US89357L1052
LEI:
Country:
United States of America
Address:
6 LIBERTY SQUARE, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Transcode Therapeutics, Inc. is a clinical-stage oncology company focused on developing targeted therapies for metastatic disease. The company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, a key regulator of metastasis. Transcode utilizes its proprietary TTX drug delivery platform, which employs tunable iron oxide nanoparticles to deliver RNA-based therapeutics specifically to cancer cells, addressing a significant challenge in the field. This platform technology has demonstrated broad potential in pre-clinical models across numerous cancer types, including breast, pancreatic, and ovarian cancer. The company aims to eradicate metastatic tumor cells that have spread from the primary tumor. Transcode recently acquired Polynoma LLC to enhance its immuno-oncology and metastatic prevention capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Transcode Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transcode Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transcode Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Vera Therapeutics, Inc. Logo
Developing biologic therapies for serious immunological diseases, focusing on IgA Nephropathy.
United States of America
VERA
Vericel Corp Logo
Develops autologous cell therapies for sports medicine and severe burn care markets.
United States of America
VCEL
Verona Pharma plc Logo
Develops innovative therapies for chronic respiratory diseases like COPD and asthma.
United States of America
VRNA
Verrica Pharmaceuticals Inc. Logo
Develops topical therapies for skin diseases like molluscum contagiosum and common warts.
United States of America
VRCA
VERTEX PHARMACEUTICALS INC / MA Logo
Develops transformative medicines for serious diseases, specializing in cystic fibrosis.
United States of America
VRTX
VERU INC. Logo
Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.
United States of America
VERU
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France
VETO
Viatris Inc Logo
A global healthcare company distributing branded and generic medicines in over 165 countries.
United States of America
VTRS
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland
VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea
308080

Talk to a Data Expert

Have a question? We'll get back to you promptly.